List of articles with "Taiho Oncology"

FDA Approval for Zipalertinib

FDA Approval for Zipalertinib

USA Princeton Taiho Oncology Zipalertinib EGFR Mutations
Taiho Oncology at ASH 2025

Taiho Oncology at ASH 2025

USA Orlando Taiho Oncology Hematologic Cancers ASH 2025
Zipalertinib Data at ESMO

Zipalertinib Data at ESMO

USA Princeton Taiho Oncology Cullinan Therapeutics Zipalertinib
Zipalertinib Insights

Zipalertinib Insights

None Taiho Oncology Cullinan Therapeutics Zipalertinib
Zipalertinib at ESMO 2025

Zipalertinib at ESMO 2025

None Berlin Taiho Oncology Zipalertinib REZILIENT2
Zipalertinib Data Presentation

Zipalertinib Data Presentation

United States Princeton Taiho Oncology Cullinan Therapeutics Zipalertinib
NCCN and Taiho Grants

NCCN and Taiho Grants

United States Plymouth Meeting Taiho Oncology NCCN Grants NSCLC Research
Positive Results from REZILIENT1

Positive Results from REZILIENT1

United States Taiho Oncology Cullinan Therapeutics Zipalertinib Princeton, New Jersey
Taiho Oncology at ASCO 2025

Taiho Oncology at ASCO 2025

USA Chicago Taiho Oncology Zipalertinib ASCO 2025
Taiho Oncology at ASCO 2025

Taiho Oncology at ASCO 2025

United States Chicago Taiho Oncology Zipalertinib ASCO 2025
NCCN Taiho Research Grants

NCCN Taiho Research Grants

United States Plymouth Meeting Taiho Oncology NCCN Oncology Gastrointestinal Cancer
Zipalertinib Trial Success

Zipalertinib Trial Success

Japan Tokyo Taiho Oncology Cullinan Therapeutics Zipalertinib
LONSURF Data Unveiled

LONSURF Data Unveiled

United States San Francisco Taiho Oncology Colorectal Cancer LONSURF
Precision Medicine Trials

Precision Medicine Trials

United States Princeton Precision Medicine Taiho Oncology Cancer Trials
ASCO GI Symposium 2025

ASCO GI Symposium 2025

United States San Francisco Taiho Oncology ASCO GI metastatic cancer
Progress in Oral Cancer Therapies

Progress in Oral Cancer Therapies

United States San Diego Blood Cancer Taiho Oncology Oral Therapies

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.